Clinical study on Shuxuening'Equation missing' combined with antipsychotics in treating chronic schizophreniacombined with antipsychotics in treating chronic schizophrenia
| Autoři: | Fanqiang Meng, Xin Yu, Mei-Lan Zhu, Hong-Wen Zhong, Chun-xiang Tan, Xue-ying Zhao, Yucun Shen, Yuhua Cui, Xu-dong Yang, Ping Liu, Lian-Cheng Zhu, He-Chun Luo, Jian-cheng Liu |
|---|---|
| Zdroj: | Chinese Journal of Integrated Traditional and Western Medicine. 3:191-194 |
| Informace o vydavateli: | Springer Science and Business Media LLC, 1997. |
| Rok vydání: | 1997 |
| Témata: | medicine.medical_specialty, Side effect, business.industry, General Medicine, Antipsychotic treatment, Placebo, Disease course, Clinical study, Internal medicine, Brief Psychiatric Rating Scale, medicine, Chronic schizophrenia, Clinical efficacy, business |
| Popis: | Objective: To make a preliminary evaluation of the clinical efficacy of Shuxuening (SXN).Methods: One hundred and forty-nine chronic schizophrenic patients were divided randomly into the SXN group and the control group in a double-blind research. SXN was given to the SXN group and placebo to the control group, and patients of both groups went on receiving the previous antipsychotic treatment. Brief Psychiatric Rating Scale (BPRS), Scale for Assessment of Negative Symptoms (SANS) and Treatment Emergent Symptoms Scale (TESS) were used to assess the effects of treatment and side effects of the drug. The evaluation was done before and during the 2nd, 4th, 6th, 10th and 12 th weeks in the course of treatment.Results: SXN was effective by BPRS evaluation (P < 0.05), and even the more effective to negative symptoms than positive symptoms by SANS evaluation (P < 0.05). It was safe and with little side effect. In addition, it was found that the incipience of SXN’ s efficacy was somehow related with the course of disease and the daily dosage used.Conclusion: SXN is worthy of further study n the treatment of chronic schizophrenia. |
| ISSN: | 1006-6497 |
| DOI: | 10.1007/bf02935137 |
| Přístupová URL adresa: | https://explore.openaire.eu/search/publication?articleId=doi_________::32a4e117a068c05f8fb812cb60329a7e https://doi.org/10.1007/bf02935137 |
| Rights: | CLOSED |
| Přírůstkové číslo: | edsair.doi...........32a4e117a068c05f8fb812cb60329a7e |
| Autor: | Fanqiang Meng, Xin Yu, Mei-Lan Zhu, Hong-Wen Zhong, Chun-xiang Tan, Xue-ying Zhao, Yucun Shen, Yuhua Cui, Xu-dong Yang, Ping Liu, Lian-Cheng Zhu, He-Chun Luo, Jian-cheng Liu |
| Rok vydání: | 1997 |
| Předmět: | |
| Zdroj: | Chinese Journal of Integrated Traditional and Western Medicine. 3:191-194 |
| ISSN: | 1006-6497 |
| DOI: | 10.1007/bf02935137 |
| Popis: | Objective: To make a preliminary evaluation of the clinical efficacy of Shuxuening (SXN).Methods: One hundred and forty-nine chronic schizophrenic patients were divided randomly into the SXN group and the control group in a double-blind research. SXN was given to the SXN group and placebo to the control group, and patients of both groups went on receiving the previous antipsychotic treatment. Brief Psychiatric Rating Scale (BPRS), Scale for Assessment of Negative Symptoms (SANS) and Treatment Emergent Symptoms Scale (TESS) were used to assess the effects of treatment and side effects of the drug. The evaluation was done before and during the 2nd, 4th, 6th, 10th and 12 th weeks in the course of treatment.Results: SXN was effective by BPRS evaluation (P < 0.05), and even the more effective to negative symptoms than positive symptoms by SANS evaluation (P < 0.05). It was safe and with little side effect. In addition, it was found that the incipience of SXN’ s efficacy was somehow related with the course of disease and the daily dosage used.Conclusion: SXN is worthy of further study n the treatment of chronic schizophrenia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink